Evidence map›Paper›PMID 36531610›Full record

ArticleMatter2023

Supramolecular filaments for concurrent ACE2 docking and enzymatic activity silencing enable coronavirus capture and infection prevention.

Caleb F Anderson, Qiong Wang, David Stern, Elissa K Leonard, Boran Sun, Kyle J Fergie, Chang-Yong Choi, Jamie B Spangler, Jason Villano, Andrew Pekosz and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Matter, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Facilitating and restraining virus infection using cell-attachable soluble viral receptors.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  3. Article
  4. Article
  5. Discovery, validation, and prodrug design of an ACE2 activator for treating bacterial infection-induced lung inflammation.Journal of controlled release : official journal of the Controlled Release Society · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Caleb F AndersonDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.
Qiong WangDivision of Pediatric Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
David SternDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.
Elissa K LeonardDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Boran SunDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.
Kyle J FergieDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.
Chang-Yong ChoiDivision of Pediatric Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Jamie B SpanglerDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.
Jason VillanoMolecular and Comparative Pathobiology, The Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Andrew PekoszDepartment of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Cory F BraytonMolecular and Comparative Pathobiology, The Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Hongpeng JiaDivision of Pediatric Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Honggang CuiDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.

Funding

The role of ACE2 in Influenza viral infection mediated immune compromise and subsequent bacterial lung infectionR01AI148446 · NIAID · JOHNS HOPKINS UNIVERSITY · PI JIA, HONGPENG · 2020 to 2024
$2.9M
ASPIRE - A Joint Johns Hopkins, Morgan State and Coppin State IRACDA ProgramK12GM123914 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI BROWN, LISA D., SARMA, SRIDEVI V. · 2018 to 2022
$2.5M
Supplement to "New ACE2 activator and its prodrug as novel therapeutic regents for inflammatory pulmonary diseases"R21AI149321 · NIAID · JOHNS HOPKINS UNIVERSITY · PI JIA, HONGPENG · 2020 to 2021
$892k
NIAID NIH HHS R01 AI148446NIAID NIH HHS R21 AI149321NIGMS NIH HHS K12 GM123914
6 · The paper itself

Abstract

Coronaviruses have historically precipitated global pandemics of severe acute respiratory syndrome (SARS) into devastating public health crises. Despite the virus's rapid rate of mutation, all SARS coronavirus 2 (SARS-CoV-2) variants are known to gain entry into host cells primarily through complexation with angiotensin-converting enzyme 2 (ACE2). Although ACE2 has potential as a druggable decoy to block viral entry, its clinical use is complicated by its essential biological role as a carboxypeptidase and hindered by its structural and chemical instability. Here we designed supramolecular filaments, called fACE2, that can silence ACE2's enzymatic activity and immobilize ACE2 to their surface through enzyme-substrate complexation. This docking strategy enables ACE2 to be effectively delivered in inhalable aerosols and improves its structural stability and functional preservation. fACE2 exhibits enhanced and prolonged inhibition of viral entry compared with ACE2 alone while mitigating lung injury

Indexed as

ACE2biomaterialscoronavirusdrug deliverypeptide amphiphilesprotein therapeuticssupramolecular filaments

Identifiers

PMID36531610
PMCPMC9743467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.